Sanavia Oncology
Founded 2020 · 14 employees on LinkedIn · 1 known investors
Sanavia develops cancer therapies—including antibody drug conjugates (ADCs), bispecific T cell engagers, and CAR-T cell therapies—that target novel epitopes in validated cancer targets. It uses an immunology-driven AI and machine learning platform to accelerate early-stage drug discovery for biotech partners and patients.
Investors · 1
Frequently asked questions
- What does Sanavia Oncology do?
- Sanavia develops cancer therapies—including antibody drug conjugates (ADCs), bispecific T cell engagers, and CAR-T cell therapies—that target novel epitopes in validated cancer targets. It uses an immunology-driven AI and machine learning platform to accelerate early-stage drug discovery for biotech partners and patients.
- Who are Sanavia Oncology's investors?
- Sanavia Oncology's investors include Two Bear Capital.